IOB - Delayed Quote USD

CureVac N.V. (0A9E.IL)

Compare
4.3740
+0.0590
+(1.37%)
At close: January 10 at 7:13:33 PM GMT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Pierre Kemula B.Sc. MD, CFO & Member of Management Board 582.02k -- 1975
Dr. Antony Blanc Ph.D. MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board 495.38k -- 1970
Dr. Malte Greune Ph.D. COO, Member of Management Board & MD 452.64k -- 1965
Dr. Ulrike Gnad-Vogt M.D., Ph.D. Sr. VP & Area Head of Oncology 371.63k -- 1973
Dr. Alexander Zehnder M.B.A., M.D. CEO, MD & Member of Management Board -- -- 1970
Dr. Myriam Mendila M.D. Chief Devel. Officer, MD & Member of the Management Board -- -- 1966
Dr. Sarah Fakih VP Corp. Communications & Investor Relations -- -- --
Mr. Marco Rau L.L.M., Ph.D. Gen. Counsel -- -- --
Mr. Thorsten Schuller Head of Corp. Communications -- -- --
Slavica Stevanovic-Heck Head of HR -- -- --

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen, 72076
Germany
49 7071 9883 0 https://www.curevac.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
904

Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate Governance

CureVac N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2024 at 12:00 PM UTC

CureVac N.V. Earnings Date

Recent Events

Related Tickers